Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3846325 | Advances in Chronic Kidney Disease | 2014 | 16 Pages |
Abstract
Membranous nephropathy, focal segmental glomerulosclerosis (FSGS), and minimal change disease (MCD) are the most common causes of idiopathic nephrotic syndrome. For many years prednisone, alkylating agents, and calcineurin inhibitors have been the standard of therapy for these patients. More effective or better tolerated treatment modalities are needed. B cell targeted therapy was recently introduced in clinical practice. In this review, we briefly summarize the current standard therapy and discuss the efficacy of BÂ cell targeted therapy in primary glomerular diseases. Observational, short-term studies suggest that rituximab is effective and comparable to standard therapy in maintaining remissions in patients with frequently relapsing or steroid-dependent MCD or FSGS. In contrast, response is limited in patients with steroid-resistant nephrotic syndrome. Rituximab also induces remissions in patients with membranous nephropathy. Controlled clinical trials on kidney endpoints are urgently needed to position BÂ cell targeted therapy in clinical practice.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Ilse M. Rood, Julia M. Hofstra, Jeroen K.J. Deegens, Jack F.M. Wetzels,